Zymedi
Zymedi is a clinical-stage biopharmaceutical company focused on transforming the role of ARSs (Aminoacyl-tRNA Synthetases) as a novel target for discovering and developing treatments for serious, life-threatening conditions lacking effective therapies or standard care. Our lead asset, ZMA001, is a first-in-class therapeutic that targets Lysyl-tRNA synthetase 1 (KARS1). By controlling monocyte and macrophage infiltration to inhibit inflammation in pulmonary blood vessels, ZMA001 is being developed as a treatment for pulmonary arterial hypertension (PAH). Currently in Phase I trials through a CRADA with the U.S. NIH, ZMA001 shows promise in addressing the root causes of PAH, a market projected to reach $9.7 billion by 2028.
7-day free trial · no credit card
Verified contacts
8
available on Kipplo
LinkedIn employees
10
11 to 50 range
Open roles
—
no listings
Distinct roles
8
indexed titles
Tech stack
0
tools in use
Monthly traffic
1
organic / mo
Sign up free to see all 8 verified contacts at Zymedi
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
8 contacts with verified email or phone · masked until revealed.
- OK
Oliver Kim
Chief Financial Officer · Other
EmailPhone - SK
Sunghoon Kim
CEO · General Business & Management
EmailPhone
Showing 2 of 8 verified contacts
Top roles at Zymedi
8 distinct titles indexed · top 8 shown.
- 1ceo
- 1chief business officer i managing director i head of business development & strategy
- 1chief financial officer
- 1cto evp
- 1director
- 1general counsel director of strategy & planning
- 1head of hr admin department
- 1메디켐 본부장
Sign up to unlock all 8 contacts at Zymedi
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 8 verified contacts at Zymedi
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.